title: AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology.
abstract: OBJECTIVE
  The use of placebo in the pediatric age group has come under increasing scrutiny. At the 2002 Annual Meeting of the American Academy of Child and Adolescent Psychiatry, the Academy's Workgroup on Research conducted a research forum. The purpose was to identify challenges and their solutions regarding the use of placebo in randomized controlled trials in pediatric psychopharmacology.
  
  
  METHODS
  Workgroups focused on problems and solutions in five areas: ethics and human subjects, research design and statistics, partnering with consumers, U.S. Food and Drug Administration and pharmaceutical industry perspectives, and psychosocial treatments.
  
  
  RESULTS
  In many but not all circumstances, inclusion of a placebo control is essential to meet the scientific goals of treatment outcome research. Innovative research designs; involvement of consumers in planning and implementing research; flexibility by industry, academia, the National Institutes of Health, and regulatory agencies acting in partnership; and concomitant use of evidence-based psychosocial services can and should assist in making placebo-controlled trials acceptable.
  
  
  CONCLUSIONS
  Properly designed placebo-controlled trials remain necessary, ethical, and feasible.
authors.affiliation: Duke University Medical Center, Durham, NC 27705, USA. jsmarch@acpub.duke.edu
authors.forename: John
authors.initials: J
authors.lastname: March
authors.forename: Christopher
authors.initials: C
authors.lastname: Kratochvil
authors.forename: Gregory
authors.initials: G
authors.lastname: Clarke
authors.forename: William
authors.initials: W
authors.lastname: Beardslee
authors.forename: Albert
authors.initials: A
authors.lastname: Derivan
authors.forename: Graham
authors.initials: G
authors.lastname: Emslie
authors.forename: Evelyn P
authors.initials: EP
authors.lastname: Green
authors.forename: John
authors.initials: J
authors.lastname: Heiligenstein
authors.forename: Stephen
authors.initials: S
authors.lastname: Hinshaw
authors.forename: Kimberly
authors.initials: K
authors.lastname: Hoagwood
authors.forename: Peter
authors.initials: P
authors.lastname: Jensen
authors.forename: Philip
authors.initials: P
authors.lastname: Lavori
authors.forename: Henrietta
authors.initials: H
authors.lastname: Leonard
authors.forename: James
authors.initials: J
authors.lastname: McNulty
authors.forename: M Alex
authors.initials: MA
authors.lastname: Michaels
authors.forename: Andrew
authors.initials: A
authors.lastname: Mossholder
authors.forename: Trina
authors.initials: T
authors.lastname: Osher
authors.forename: Theodore
authors.initials: T
authors.lastname: Petti
authors.forename: Ernest
authors.initials: E
authors.lastname: Prentice
authors.forename: Benedetto
authors.initials: B
authors.lastname: Vitiello
authors.forename: Karen
authors.initials: K
authors.lastname: Wells
mesh_terms: D000293:Adolescent; D000296:Adolescent Psychiatry; D002648:Child; D002665:Child Psychiatry; D004493:Education; D006801:Humans; D010919:Placebos / Q000627:therapeutic use*; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012955:Societies, Medical; D014481:United States
chemical_list: D010919:Placebos; D011619:Psychotropic Drugs